Nelfinavir protease inhibitor study recruiting. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.

Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Nelfinavir protease inhibitor study recruiting. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714.

AIDS Treat News. 1996 Aug 23;(No 253):1. Unique Identifier : AIDSLINE AIDS/96701858

Abstract: Agouron Pharmaceuticals, Inc. is recruiting 200 participants in 8 U.S. cities for its clinical trial for nelfinavir (VIRACEPT), an experimental protease inhibitor. Volunteers must already be taking a nucleoside analog drug such as AZT, ddI, ddC, d4T, or 3TC, and have a CD4 count under 100. All volunteers will receive 750 mg of nelfinavir three times a day; half of them will be asked to stay on the nucleoside analog they are currently using while the other half will be assigned a different nucleoside analog. For more information, individuals may contact Agouron Pharmaceuticals, Inc.

Keywords: HIV Infections/*DRUG THERAPY HIV Protease Inhibitors/*THERAPEUTIC USE Human Randomized Controlled Trials NEWSLETTER ARTICLE
961230
M96C1440

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .